Study provides reassuring data over link between qHPV vaccine and multiple sclerosis

Study looks at quadrivalent human papillomavirus (qHPV) vaccine and development of multiple sclerosis (MS) and other demyelinating diseases.

Case reports have prompted concern about a possible link between the quadrivalent human papillomavirus (qHPV) vaccine and development of multiple sclerosis (MS) and other demyelinating diseases.

This link was investigated in a cohort of nearly 4 million girls and women in Denmark and Sweden who were followed up from 2006 until 2013, nearly 800,000 of whom received the qHPV vaccine. The incidence of demyelinating diseases did not differ significantly between vaccinated and unvaccinated individuals, with adjusted rate ratios of 0.90 (95% confidence interval 0.70–1.15) for MS and 1.00 (95% CI 0.80–1.26) for other demyelinating diseases.

“Our study adds to the body of data that support a favourable overall safety profile of the qHPV vaccine,” write the study authors in JAMA
[1] (online, 6 January 2015). 

References

 [1] Scheller NM, Svanström H, Pasternak B et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015;313(1):54-61. doi:10.1001/jama.2014.16946.

Last updated
Citation
The Pharmaceutical Journal, PJ, 17 January 2015, Vol 294, No 7845;294(7845):DOI:10.1211/PJ.2015.20067540